Enhancement of cytotoxic and pro-apoptotic effects of 2-aminophenoxazine-3-one on the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2, and the rat normal hepatocellular cell line RLN-10 in combination with 2-deoxy-D-glucose

AKIRA TAKEMURA1*, XIAO-FANG CHE2*, TAKAFUMI TABUCHI1, SHOTA MORIYA2, KEISUKE MIYAZAWA2 and AKIO TOMODA2

1Fourth Department of Surgery, Tokyo Medical University, Ibaraki Medical Center, 3-20-1 Chuo, Inashiki, Ibaraki 300-0395; 2Department of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Tokyo 160-8402, Japan

Received August 15, 2011; Accepted October 3, 2011

DOI: 10.3892/or.2011.1531

Correspondence to: Dr Akio Tomoda, Department of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Tokyo 160-8402, Japan E-mail: tomoda@tokyo-med.ac.jp

*Contributed equally

Key words: 2-aminophenoxazine-3-one, 2-deoxy-D-glucose, hepatocellular carcinoma cells, normal hepatocellular cells, pro-apoptotic effect

Abstract. The cytotoxic and pro-apoptotic effects of a single dose of 2-aminophenoxazine-3-one (Phx-3) or 2-deoxyglucose (2-DG) or of a combined dose of Phx-3 and 2-DG were studied in the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2 and the rat normal hepatocellular cell line RLN-10. The number of viable cells decreased in a dose-dependent manner, when dRLh-84, HepG2 or RLN-10 cells were treated with 2-DG (0.5-20 mM) or Phx-3 (1-50 μM) alone at 37˚C for 48 h. When these cells were treated with 10 mM 2-DG and different concentrations of Phx-3, the number of viable cells decreased dose-dependently and in an additive manner for these agents. A single dose of 2 or 10 μM Phx-3 induced apoptotic morphology characterized by nuclear condensation and cell shrinkage in dRLh-84, HepG2 and RLN-10 cells, while a single dose of 10 mM 2-DG did not. When Phx-3 (2 or 10 μM) treatment was combined with 2-DG (10 mM) treatment in these three cell lines, the cells with apoptotic morphology increased extensively, which was confirmed by flow cytometric analysis. In addition, autophagic morphology characterized by cytosolic vacuole formation was significantly increased in the hepatocellular carcinoma cell lines dRLh-84 and HepG2 but not in the normal hepatocellular cell line RLN-10 after a single dose of Phx-3 or 2-DG or a combined dose of Phx-3 and 2-DG. Furthermore, when dRLh-84 and HepG2 cells were treated with Phx-3 alone or a combined dose of Phx-3 and 2-DG, depolarization of the mitochondria was extensive, but that of the normal cell line RLN-10 was not. These results may imply that the mechanism for the apoptosis of hepatocellular carcinoma cells caused by Phx-3 alone or a combined dose of Phx-3 and 2-DG differs from that of the normal cell line RLN-10. The present results demonstrate that Phx-3 alone may be beneficial for targeting liver cancer and that its anticancer activity may be enhanced by 2-DG. However, a combined dose of Phx-3 and 2-DG may exert adverse effects on normal liver cells, as evidenced by the cytotoxic and pro-apoptotic effects of the combined treatment in the rat normal hepatocellular cell line RLN-10.

Introduction

Cancer cells are generally characterized by paradoxical behavior recognized as the Warburg effect (1), i.e., augmented rates of glycolysis and suppressed mitochondrial oxidative phosphorylation under aerobic conditions in these cells. Therefore, suppression of glycolytic metabolism in malignant cells has been a target of cancer treatment (2-4). Since a low intracellular pH (pHi) inhibits the activity of glycolytic enzymes, including phosphofructokinase in both normal cells and in cancer cells (5,6), leading to suppression of the glycolytic metabolism, it is reasonable that agents that reduce pHi may be candidates for cancer treatment (7-9). Amiloride and its derivative, 5-(N,N-hexamethylene) amiloride (HMA) have been shown to decrease pHi in cancer cells, thereby exerting anticancer activity (10,11). Che and colleagues (12-15) have demonstrated that an oxidative phenoxazine, 2-aminophenoxazine-3-one (Phx-3) exerts cytotoxic effects against a variety of cancer cells and causes apoptosis of these cells in vitro, by reducing pHi in these cells and thereby perturbing the intracellular homeostasis, including the glycolytic metabolism.
Another measure to prevent glycolysis in normal cells and cancer cells is to use 2-deoxy-D-glucose (2-DG), which has been shown to suppress the glycolytic metabolism in these cells, due to the specific inhibition of hexokinase, an initial rate-limiting enzyme of the glycolytic pathway (16), and therefore, has been applied to animal model studies and human clinical trials for cancer treatment (17,18). 2-DG itself does not exert severe adverse effects on the human body (18). This compound, a derivative of glucose, does not necessarily suppress the growth of cancer in animals with a single dose (17). However, a combined dose of 2-DG and anticancer agents, such as cisplatin, metformin and doxorubicin, causes extensive apoptotic cell death of cancer cells (19-21). This characteristic action of a combined dose of 2-DG and anticancer drugs was considered to be due to suppression of the glycolytic pathway and inhibition of the prosurvival pathway, including Akt (B kinase) (22,23). Therefore, it will be interesting to study how a combined dose of Phx-3 and 2-DG may affect the growth of cancer cells.

Hepatocellular carcinoma, which is increasing worldwide (24) and is characterized by intra- and extrahepatic invasiveness (25), is resistant to anticancer agents. Agents to prevent the growth of hepatocellular cancer cells by inducing the apoptosis of these cancer cells are urgently required. Therefore, it is of interest to examine whether Phx-3 may exert anticancer activity against hepatocellular cancer cells, in a single or a combined dose with 2-DG, since there is no report on the cytotoxic and pro-apoptotic effects of Phx-3 on hepatocellular cancer cells. Moreover, it will be important to investigate how a combined dose of Phx-3 and 2-DG may exert cytotoxic and pro-apoptotic effects against normal hepatocellular cells, in order to study the adverse effects of the combination of these compounds on the normal liver.

In this study, we investigated the effects of a single dose of Phx-3 or 2-DG and those of the combined use of Phx-3 and 2-DG on hepatocellular carcinoma cell lines, the rat dRLh-84 and the human HepG2, as well as on the normal rat hepatocellular cell line RLN-10, in terms of the pro-apoptotic and cytotoxic effects in these cells.

**Materials and methods**

*Reagents. Phx-3 was prepared by reacting o-aminophenol with bovine erythrocyte suspension, according to the method of Nakachi et al (26). The chemical structure of Phx-3 is depicted in Fig. 1. Phx-3 was dissolved in a mixture of dimethylsulfoxide (DMSO) and ethyl alcohol (3:1) as a vehicle to make a 20-mM solution. 2-Deoxy-D-glucose (2-DG) (Wako Pure Chemicals, Tokyo, Japan) was dissolved in distilled water to make a 20-mM solution. 2-Deoxy-D-glucose (2-DG) (Wako Pure Chemicals, Tokyo, Japan) was dissolved in distilled water to make a 20-mM solution. 2-Deoxy-D-glucose (2-DG) (Wako Pure Chemicals, Tokyo, Japan) was dissolved in distilled water to make a 20-mM solution.

*Cell lines and culture condition. The rat hepatocellular carcinoma cell line dRLh-84, the rat normal liver cell line RLN-10 and the human hepatocellular carcinoma cell line HepG2 which were obtained from the Health Science Research Resources Bank (Osaka, Japan), were cultured in DMEM supplemented with 10% fetal calf serum (FCS) (PAA Laboratories, GmbH, Austria), 2 mM glutamine and 100 U/ml of penicillin. All of the cells were cultured in a humidified incubator containing 5% CO₂/95% air at 37°C.

*Assessment of cell morphology. For morphological assessment, each of the three cell lines [the rat hepatocellular carcinoma cell line, dRLh-84, the rat normal liver cell line, RLN-10 and the human hepatocellular carcinoma cell line HepG2 (2x10⁴)] were incubated for 24 h, with or without 2 or 10 µM Phx-3 and/or 10 mM 2-DG in a 12-well plate. The cells were then digested with trypsin, and a suspension of each cell line was sedimented and fixed on a slide glass, using a Shandon Cyotospin II (Shandon, Pittsburgh, PA, USA). The preparations were then stained with May-Grünwald-Giems solution and examined by a BZ-9000 digital microscope (Keyence Co., Osaka, Japan).

*Estimation of viability of the hepatocellular carcinoma cell lines dRLh-84 and HepG2 and the rat normal cell line RLN-10 treated with different concentrations of Phx-3 or 2-DG alone or in combination with 2-DG. The hepatocellular carcinoma cell lines dRLh-84 and HepG2 and the rat normal cell line RLN-10 (5x10⁴) were incubated with or without various concentrations of Phx-3 or 2-DG for 48 h in 96-well plates. At 24 or 48 h, a solution of CellTiter-Blue™ (Promega, Madison, WI) (5 mg/ml) was added to each well, and the cells were incubated for an additional 1.5 h. The fluorescence was then recorded at 560 nm excitation/590 nm emission wavelengths.

*Apoptosis detection. Apoptotic cells were quantitatively evaluated by flow cytometry, using the Annexin-V-fluorescein staining kit (Wako Pure Chemicals). Each of the three cell lines dRLh-84, RLN-10 and HepG2 (2x10⁴) were treated with 0, 2.5 or 10 µM Phx-3 for 18 h with or without 2 or 10 mM 2-DG. The cells were then harvested and washed once with phosphate-buffered saline (PBS, pH 7.4). An aliquot of 100 µl of cell suspension was stained with 2 µl of fluorescein isothiocyanate (FITC)-labeled Annexin-V (Annexin-V-FITC) and propidium iodide (PI). Samples were incubated for 15 min at room temperature, after which 1 ml of binding buffer was added. The levels of fluorescent staining of the cells were analyzed using a flow cytometer (Partec PAS, Partec, Münster, Germany) to estimate the population of apoptotic cells at the early stage (Annexin-V positive and PI negative fractions) and the late apoptotic stage (Annexin-V positive and PI positive fractions), in each of three cell lines treated with different concentrations of Phx-3 with or without 10 mM 2-DG.

*Detection of loss of the mitochondrial membrane potential in hepatocellular carcinoma cells (dRLh-84 and HepG2) and rat normal hepatocellular cells (RLN-10). The loss of mitochondrial membrane potential in the two hepatocellular carcinoma cell lines, dRLh-84 and HepG2, and the rat normal hepatocellular cell line, RLN-10, was examined by
5,5’,6,6’-tetrachloro-1,1’,3,3’-tetracyclohexylcarbocyanine iodide (JC-1). Briefly, the cells (2×10⁴) were seeded in 12-well plates and were treated with 0, 2, 5, or 10 µM Phx-3 for 6 h with or without or 2 or 10 mM 2-DG. The cells were rinsed twice with PBS, then stained with 1 ml 10% RPMI-1640 medium containing 5 µmol/l JC-1 (Molecular Probes, USA) for 30 min at 37°C. The cells were then rinsed twice with ice-cold PBS, resuspended in 1-ml ice-cooled PBS, and instantly assessed for red and green fluorescence using a flow cytometer (Partec). JC-1 monomer green signals were detected at an emission wavelength of 535 nm (excitation wavelength 485 nm) and the JC-1 aggregate red signals at an emission wavelength of 595 nm (excitation wavelength 540 nm).

**Immunoblotting analysis.** Immunoblotting of LC3B and p62 in HepG2 cells was performed as previously described (27). HepG2 cells treated with Phx-3 and/or 2-DG were lysed with RIPA lysis buffer (Santa Cruz Biotechnology Inc., Santa Cruz, CA) containing 1 mM PMSF, 0.15 U/ml aprotinin, 10 mM EDTA, 10 mg/ml sodium fluoride, and 2 mM sodium orthovanadate. Cellular proteins were separated by SDS-PAGE and transferred onto Immobilon-P membranes (Millipore, Bedford, MA). The membranes were probed with the primary antibodies (Abs) anti-microtubule-associated protein 1 light chain 3 (LC3) B Ab (Novus Biologicals, Inc., Littleton, CO), anti-p62 Ab (Santa Cruz, CA), and anti-GAPDH monoclonal (m) Ab (Santa Cruz, CA). Immunoreactive proteins were detected with horseradish peroxidase-conjugated secondary Abs and an enhanced chemiluminescence reagent (ECL) (Millipore). Densitometry was performed using a Molecular Imager, ChemiDoc XRS System (Bio-Rad, Richmond, CA).

**Results**

First, we studied the cytotoxic effects of different concentrations of Phx-3 and 2-DG on the rat hepatocellular carcinoma cell line dRLh-84 (Fig. 2A), the human hepatocellular carcinoma cell line HepG2 (Fig. 2B) and the rat normal hepatocellular cell line RLN-10 (Fig. 2C), which were examined for 48 h. As seen in Fig. 2A, a single dose of 2-DG (0.5-20 mM) or Phx-3 (1-50 µM) caused a dose-dependent decrease of viable dRLh-84 cells at 24 and 48 h. The number of viable cells was decreased to 60 and 40% of the control (without 2-DG) in the presence of 10 mM 2-DG at 24 and 48 h, respectively (the upper columns in Fig. 2A), and the viable cells disappeared in the presence of 10 µM or more Phx-3, at 24 and 48 h, in dRLh-84 cells (the lower columns in Fig. 2A). The cytotoxic effects of the combined dose of Phx-3 (1-50 µM) and 10 mM 2-DG were additive in dRLh-84 cells (lower columns in Fig. 2A). Similar results were obtained for HepG2 cells (Fig. 2B) and the RLN-10 cells (Fig. 2C) treated with a single dose of 2-DG or Phx-3 or a combined dose of Phx-3 and 2-DG at different concentrations for 48 h. The IC₅₀ of Phx-3 was estimated as 7.50±0.20 µM for dRLh-84 cells, 6.58±0.61 µM for HepG2 cells and 5.97±0.20 µM for RLN-10 cells.

Next, we studied the morphological changes of the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2 and the rat normal hepatocellular cell line RLN-10 with or without Phx-3 (2 or 10 µM) and/or 2-DG (10 mM) (Fig. 3). There were a few apoptotic features, including a condensed nucleus and cell shrinkage, in the control dRLh-84 cells without Phx-3 and 2-DG treatment (the upper left two panels in Fig. 3A), or in dRLh-84 cells with 10 mM 2-DG alone (the upper right two panels in Fig. 3A). However, in the latter case, numerous vacuoles possibly associated with autophagy were observed in the cytosol of dRLh-84 cells treated with 10 mM 2-DG alone. When 2 µM Phx-3 was added to the dRLh-84 cells, the number of apoptotic cells with condensed nucleus and cell shrinkage increased significantly (the lower left two panels), and included many vacuoles in the cytosol, suggesting that apoptosis and autophagy are proceeding simultaneously. The number of cells with extremely condensed nuclei and cell shrinkage increased in dRLh-84 cells treated with 2 µM Phx-3 and 10 mM 2-DG (the lower right two panels in Fig. 3A), indicating that almost every cell underwent the apoptotic cell death.

Similar morphological changes were observed in HepG2 cells (Fig. 3B). Specifically, few apoptotic cells were seen in HepG2 cells treated with 10 mM 2-DG alone, but vacuole formation was observed in the cytosol of the cells (the upper two right panels). After exposure of the cells to 10 µM Phx-3 alone, the HepG2 cells experienced apoptosis, accompanied by vacuole formation in the cells (the lower left two panels). When 10 µM Phx-3 and 10 mM 2-DG were administered to HepG2 cells, the viable cells decreased and the remaining cells exhibited typical apoptotic morphology with many cytosolic vacuoles (the lower right two panels in Fig. 3B). This observation was further examined, as described later in connection with Fig. 6.

When the rat normal hepatocellular cell line RLN-10 was singly treated with 2-DG (10 mM), there was no significant apoptotic features or cytosolic vacuole formation (the upper two right panels in Fig. 3C). However, apoptotic morphology was observed when cells were treated singly with Phx-3 (2 µM), but minimal vacuole formation was observed in this case. When RLN-10 cells were treated with 2 µM Phx-3 and 10 mM 2-DG, the viable cells decreased and the remaining cells exhibited typical apoptotic morphology, but with minimal vacuole formation (the lower right two panels in Fig. 3C), suggesting that the combined dose of Phx-3 and 2-DG induced apoptotic cell death in RLN-10 cells without causing autophagy.

In order to confirm apoptotic cell death in the three afore-mentioned hepatocellular cell lines, we examined the population of apoptotic cells in these cell lines when treated with Phx-3 or/and 2-DG for 18 h (Fig. 4). Fig. 4A presents representative data obtained by flow cytometry for the population of apoptotic cells in dRLh-84 cells, which were treated with Phx-3 alone (0, 2, 5 and 10 µM), 2-DG alone (0, 2 and 10 mM), or with both Phx-3 (2, 5 and 10 µM) and 2-DG (2 or 10 mM) for 18 h. Subsequently, it was found that the population of late stage apoptotic cells [Annexin-V(-) and PI(+)] increased up to 90.5, 92.8 and 91.5% in dRLh-84 cells treated with a single dose of 2, 5 and 10 µM Phx-3, respectively. The population of late stage apoptotic cells increased up to 88, 94.5 and 95.4% in the presence of 2, 5 and 10 µM Phx-3 in combination with 2 mM 2-DG, and up to 92.7, 93.5, and 92% in combination with 10 mM 2-DG (these data are depicted as histograms in Fig. 4B). In these cases, the population of early apoptotic cells [Annexin-V(+) and PI(−)] and necrotic cells [Annexin-V(−) and PI(−)]
Figure 2. Cytotoxic effects of a single dose of Phx-3 or 2-DG and a combined dose of Phx-3 and 2-DG on the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2, and the rat normal liver cell line RLN-10. Each of the three cell lines was treated with a single dose of Phx-3 (1-50 µM) or 2-DG (0.5-20 mM) or a combined dose of Phx-3 (1-50 µM) and 2-DG (10 mM), and the number of viable cells (as a percentage of the control) was estimated fluorometrically by using the CellTiter-Blue™ method. Open triangles, 0.5-20 mM 2-DG; open circles, 1-50 µM Phx-3; closed circles, 10 mM 2-DG plus 1-50 µM Phx-3. (A) Rat hepatocellular carcinoma cell line dRLh-84; (B) human hepatocellular carcinoma cell line HepG2; (C) rat normal liver cell line RLN-10.
and PI (+) was negligible. These results indicate that almost all dRLh-84 cells experienced late stage apoptotic cell death following treatment with 2 µM or more Phx-3 for 18 h, with or without 2-DG.

The histograms in Fig. 4B-D reflect the population of late stage apoptotic cells in dRLh-84, HepG2 and RLN-10 cells treated with Phx-3 or 2-DG or a combined dose of Phx-3 and 2-DG for 18 h, which was analyzed by flow cytometry. It is evident in Fig. 4C that a single dose of Phx-3 (2-10 µM) and a combined dose of Phx-3 (2-10 µM) and 2-DG (2 or 10 mM) greatly increased the population of late apoptotic cells, while 2-DG alone caused an increase in late apoptotic cells in the human hepatocellular carcinoma cell line HepG2, dependent on the dose of Phx-3. For a combined dose of 2 µM Phx-3 and 10 mM 2-DG, Phx-3 caused pro-apoptotic effects on HepG2 cells in an additive manner, because the difference (20%) between the apoptotic cells in HepG2 cells treated with 10 mM 2-DG and 2 µM Phx-3 (apoptosis fraction, 80%) and those treated with 10 mM 2-DG and 0 µM Phx-3 (apoptosis fraction, 60%) is comparable to the difference (21%) between the apoptotic cells in HepG2 cells treated with 0 mM 2-DG and 2 µM Phx-3 (apoptosis fraction, 39%) and those treated with 0 mM 2-DG and 0 µM Phx-3 (apoptosis fraction, 18%) (Fig. 4C).

In contrast, a combined dose of 2 µM Phx-3 with 10 mM 2-DG exerted synergistic pro-apoptotic effects in the rat normal hepatocellular cell line RLN-10, because the apoptotic cells increased up to 73% in the RLN-10 cells treated with 2 µM Phx-3 and 10 mM 2-DG, while 2 µM Phx-3 or 10 mM 2-DG alone did not increase the population of apoptotic RLN-10 cells (Fig. 4D).

Since it has been recognized that depolarization of the mitochondria is induced prior to the apoptotic events in cancer cells treated with anticancer agents (28,29) and Phx-3 (14,30,31), we studied the effect of Phx-3 and 2-DG on the depolarization of the mitochondria in the hepatocellular carcinoma cell lines, dRLh-84 and HepG2, the rat normal cell line, RLN-10. Fig. 5A presents the effect of Phx-3 (0, 2 or 5 µM) on depolarization of the mitochondria in the rat hepatocellular carcinoma dRLh-84 cells, analyzed by flow cytometry. Consequently, significant depolarization of the mitochondria in dRLh-84 was caused by 5 µM Phx-3. The histograms in Fig. 5B-D demonstrate depolarization of the mitochondria in dRLh-84 cells, HepG2 cells and RLN-10 cells.

Figure 3. Morphological changes in the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2 and the rat normal liver cell line RLN-10 treated with a single dose of 2-DG, Phx-3 or a combined dose of 2-DG and Phx-3. The left four panels in each figure depict cells treated without 2-DG and Phx-3 or with 2 or 10 µM Phx-3 alone; the right four panels in each figure depict cells treated with 10 mM 2-DG alone or 10 mM 2-DG plus 2 or 10 µM Phx-3. Magnification, x400 or x1000. Morphology of (A) the rat hepatocellular carcinoma cell line dRLh-84; (B) the human hepatocellular carcinoma cell line, HepG2; (C) the rat normal liver cell line, RLN-10.
with different concentrations of Phx-3 and/or 2-DG. It is noteworthy that depolarization of the mitochondria was induced in hepatocellular carcinoma cells including dRLh-84 cells and HepG2 cells, dependent on the dose of Phx-3, though 2-DG did not cause depolarization of the mitochondria in these cells (Fig. 5B and C), and that depolarization of the mitochondria was not induced in the rat normal RLN-10 cells in the presence of various concentrations of Phx-3 and/or 2-DG, compared with the control without Phx-3 and 2-DG (Fig. 5D).

As seen in Fig. 3A and B, a significant increase of cytosolic vacuoles was observed in the hepatocarcinoma cell lines, dRLh-84 and HepG2 treated with 2 or 10 µM Phx-3. In addition, combined treatment with Phx-3 and 2-DG appeared to enhance the number of cytosolic vacuoles in these hepatocar-
cinoma cells (Fig. 3A and B), suggesting that autophagy might be induced in response to both 2-DG and Phx-3 in dRLh-84 and HepG2 cells. Thus, we performed immunoblotting using anti-LC3B and anti-p62 antibodies, in order to investigate whether or not autophagy was induced in HepG2 cells after treatment with Phx-3 and/or 2-DG. As shown in Fig. 6, an increased ratio of LC3B-II/LC3B-I (5.06) as well as a decreased p62 protein level was observed after 16-h exposure of HepG2 cells to Phx-3. This indicated that autophagy was induced in HepG2 cells in response to Phx-3. 2-DG also induced autophagy but to a much lesser extent than Phx-3. Since combined treatment with Phx-3 plus 2-DG exhibited potent cytotoxicity against HepG2 cells (Fig. 3B), making it difficult to obtain a sufficient amount of protein from the cells, enhanced autophagy induction due to the combination of 2-DG and Phx-3 was not evident as seen in Fig. 6. However, these data suggest that autophagy was involved during cytotoxic induction in response to Phx-3 and 2-DG.

Discussion

Phx-3 has been shown to exert strong anticancer activity against a variety of cancer cell lines in vitro and in vivo (12-15,30-34). However, the anticancer activity of this oxidative phenoxazine against hepatocellular carcinoma cells has not been investigated, though this kind of malignant tumor is intractable to chemotherapy, and its incidence is increasing worldwide (24,25). We found in the present study that 10 µM or more Phx-3 exerted strong cytotoxic effects on the rat hepatocellular carcinoma cell line dRLh-84 and the human hepatocellular carcinoma cell line HepG2 and rat normal liver cell line RLN-10 treated with or without Phx-3 and 2-DG. (A) Flow cytometric analysis of the depolarized mitochondria in dRLh-84 cells treated with or without 2 or 5 µM Phx-3 for 6 h. Population of cells with the depolarized mitochondria in (B) dRLh-84 cells treated with or without 2 or 5 mM 2-DG or 2, 5 or 10 µM Phx-3. (C) HepG2 cells treated with or without 2 or 10 mM 2-DG or 2, 5 or 10 µM Phx-3 or (D) in RLN-10 cells treated with or without 2 or 10 mM 2-DG or 2, 5 or 10 µM Phx-3.
The mechanism for the anticancer activity of Phx-3 in hepatocellular carcinoma cells may be explained primarily by depolarization of the mitochondria in cells treated with this phenoxazine, as demonstrated in Fig. 5B and C, and in recent reports (30,31). This view is also supported, by the fact that depolarization of the mitochondria has been recognized as an important change in the final stage of apoptotic events in cancer cells (28,29).

We found that 2-DG, an inhibitor of hexokinase that suppresses the glycolytic metabolism and thereby decreases ATP levels in cancer cells (16), does not necessarily exert strong anticancer activity against the hepatocarcinoma cell lines dRLh-84 and HepG2, because a small increase (moderate increase) of the apoptotic cells was indicated with 2-DG alone in dRLh-84 (Fig. 4B) or HepG2 (Fig. 4C). The minimal or moderate anticancer activity of 2-DG on these hepatocarcinoma cells may be associated with autophagy induction by 2-DG, which has been considered as an important mechanism of resistance to cellular stress such as deficiency of ATP (22,23).

As shown in Fig. 5B and C, and in the present results, the coordination of these compounds in combination with various anticancer agents such as cisplatin and metformin.

The pro-apoptotic effects of a combined dose of Phx-3 and 2-DG in the normal rat cell line RLN-10 were extensive and synergistic (Fig. 4D). The pro-apoptotic effects of a combined dose of Phx-3 and 2-DG, which caused extensive cytotoxic and pro-apoptotic effects on a rat normal hepatocellular cell line RLN-10, may have adverse effects on the liver when used in vivo, though this view should be confirmed by further examination.

Depolarization of the mitochondria has been recognized as an important change in the final stage of apoptotic events in cancer cells (28,29). We found that significant depolarization of the mitochondria was induced in dRLh-84 and HepG2 cells treated with 2 µM or more Phx-3 for 18 h, without being affected by the presence of 2-DG (Fig. 5B and C). In spite of the strong action of Phx-3 on depolarizing the mitochondria in hepatocarcinoma cell lines, Phx-3 did not depolarize the mitochondria in the normal rat cell line RLN-10, with or without 2-DG (Fig. 5D). Such differences in the sensitivity of cancer cells and normal cells to Phx-3 have been indicated by Che et al (14). They demonstrated that Phx-3 caused depolarization of the mitochondria in a variety of cancer cells from different organs, but has not this effect in normal cells, including human umbilical vein endothelial cells and HEL fibroblast cells. It is unclear how this difference in the sensitivity of the mitochondria to depolarization due to Phx-3 between cancer cells and normal cells comes about. There may be differences in the nature of the mitochondria between these cells, or some different mechanisms for regulating the mitochondrial depolarization between these cells. However, such a difference would be advantageous for the therapeutic strategy of selectively causing apoptosis in cancer cells.

In conclusion, Phx-3 itself was found to have cytotoxic and pro-apoptotic activity against hepatocellular carcinoma cells, and exerted much stronger anticancer activity against these cells when they were treated with Phx-3 and 2-DG together. However, the adverse effects of a combined dose of Phx-3 and 2-DG should be considered for chemotherapeutic application to liver carcinoma, because the viability of rat normal hepatocellular cells was greatly affected by a combined dose of these compounds.

Acknowledgements

The present study was supported by funds from the High-Tech Research Project for Private Universities and a matching fund subsidy from the Ministry of Education, Culture, Sports and Technology, Japan (2008-2013), and by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports and Technology, Japan (2009-2010) (no. 21790324).
References